{"title":"The Impact of Time in Target Range for Systolic Blood Pressure on Left Ventricular Hypertrophy.","authors":"Jianjiao Wang, Wen Li, Gui Man, Yang Liu, Siyu Wang, Shouling Wu, Wei Huang","doi":"10.1093/ajh/hpaf141","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>We aimed to explore the association between systolic blood pressure time-in-target range (SBP-TTR) and left ventricular hypertrophy (LVH).</p><p><strong>Methods: </strong>A total of 33,818 participants of the Kailuan Study who underwent echocardiography and had participated in at least two health check-ups between 2006 and 2020. The target systolic blood pressure (SBP) ranges are defined as 120-140 mmHg and 110-130 mmHg, respectively. SBP-TTR was calculated by linear interpolation. Poisson regression models were used to assess relative risk (RR) and 95% confidence intervals (CIs) for the associations of 120-140 mmHg SBP-TTR and 110-130 mmHg SBP-TTR with LVH.</p><p><strong>Results: </strong>When the SBP target range was defined as 120-140mmHg, in multivariable-adjusted models, compared to the reference group (SBP-TTR ≤ 25%), LVH risk was significantly reduced in the 75% < SBP-TTR ≤ 100% group, (RR: 0.94, 95% CI: 0.89-0.99). When the SBP target range was defined as 110-130mmHg, compared to the reference group (SBP-TTR ≤ 25%),there was significantly reduced in LVH risk in the 25%<SBP-TTR≤50%(RR:0.89,95%CI:0.83-0.94)、50%<SBP-TTR≤75%(RR:0.85,95%CI:0.79-0.91) and 75%< SBP-TTR≤100%(RR:0.81,95%CI:0.76-0.86)groups. Analysis using restricted cubic splines revealed a linear, dose-response relationship between SBP-TTR and LVH risk.</p><p><strong>Conclusions: </strong>With increased SBP-TTR associated with a reduced risk of LVH, demonstrating a clear dose-response relationship. Compared to an SBP-TTR range of 120-140 mmHg, maintaining SBP-TTR at 110-130 mmHg more effectively reduces LVH risk.</p>","PeriodicalId":7578,"journal":{"name":"American Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajh/hpaf141","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: We aimed to explore the association between systolic blood pressure time-in-target range (SBP-TTR) and left ventricular hypertrophy (LVH).
Methods: A total of 33,818 participants of the Kailuan Study who underwent echocardiography and had participated in at least two health check-ups between 2006 and 2020. The target systolic blood pressure (SBP) ranges are defined as 120-140 mmHg and 110-130 mmHg, respectively. SBP-TTR was calculated by linear interpolation. Poisson regression models were used to assess relative risk (RR) and 95% confidence intervals (CIs) for the associations of 120-140 mmHg SBP-TTR and 110-130 mmHg SBP-TTR with LVH.
Results: When the SBP target range was defined as 120-140mmHg, in multivariable-adjusted models, compared to the reference group (SBP-TTR ≤ 25%), LVH risk was significantly reduced in the 75% < SBP-TTR ≤ 100% group, (RR: 0.94, 95% CI: 0.89-0.99). When the SBP target range was defined as 110-130mmHg, compared to the reference group (SBP-TTR ≤ 25%),there was significantly reduced in LVH risk in the 25%
Conclusions: With increased SBP-TTR associated with a reduced risk of LVH, demonstrating a clear dose-response relationship. Compared to an SBP-TTR range of 120-140 mmHg, maintaining SBP-TTR at 110-130 mmHg more effectively reduces LVH risk.
期刊介绍:
The American Journal of Hypertension is a monthly, peer-reviewed journal that provides a forum for scientific inquiry of the highest standards in the field of hypertension and related cardiovascular disease. The journal publishes high-quality original research and review articles on basic sciences, molecular biology, clinical and experimental hypertension, cardiology, epidemiology, pediatric hypertension, endocrinology, neurophysiology, and nephrology.